Approaches and Outcomes to Distal Cholangiocarcinoma

被引：17

作者：

Lee, Rachel M. ^{[1
]}

Maithel, Shishir K. ^{[2
]}

机构：

[1] Emory Univ, Sch Med, Dept Surg, Div Surg Oncol,Winship Canc Inst, 13658 Clifton Rd,4th Floor, Atlanta, GA 30322 USA

[2] Emory Univ, Sch Med, Dept Surg,Div Surg Oncol, Emory Liver & Pancreas Ctr,Winship Canc Inst, 13658 Clifton Rd,4th Floor, Atlanta, GA 30322 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2019年 / 28卷 / 04期

关键词：

Distal cholangiocarcinoma; Extrahepatic cholangiocarcinoma; Adjuvant therapy; Risk factors; Surgery; BILE-DUCT CANCER; FINE-NEEDLE-ASPIRATION; BILIARY-TRACT CANCER; B-VIRUS-INFECTION; INTRAHEPATIC CHOLANGIOCARCINOMA; ADJUVANT CHEMOTHERAPY; ENDOSCOPIC ULTRASOUND; P53; ANTIBODY; RISK-FACTORS; PHASE-II;

D O I：

10.1016/j.soc.2019.06.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Distal cholangiocarcinoma is a rare malignancy with a dismal prognosis. Because of its location and aggressive nature, patients often present with locally advanced or metastatic disease, and effective treatment options are limited. For patients with resectable disease, surgery is the only chance for cure, but achieving an R0 resection is paramount. Optimal adjuvant therapy in resectable disease remains under investigation. Randomized controlled trials investigating neoadjuvant therapy and its impact on resectability and long-term outcomes are needed to continue to improve the outcomes of patients with distal cholangiocarcinoma.

引用

页码：631 / +

页数：15

共 69 条

[1]

American Cancer Society, 2018, FACTS FIG 2018

[2]

[Anonymous], 2012, GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012

[3]

[Anonymous], 2019, CLIN PRACT GUID ONC

[4] SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma [J].